Systemic sclerosis (SSc) is a complex autoimmune disease that occurs in a genetically susceptible host. Genetic studies performed so far reveal that multiple genetic loci contribute to disease susceptibility in…
Maureen D. Mayes, MD, MPH, Editor Since the last issue of Rheumatic Disease Clinics of North America on systemic sclerosis (SSc, scleroderma), there have been great advances in our understanding…
Michael H. Weisman, MD, Consulting Editor Systemic Sclerosis (SSC), of all of the rheumatic diseases, is clearly the most challenging in terms of early diagnosis, understanding its pathogenesis, managing the…
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA www.rheumatic.theclinics.com Consulting Editor MICHAEL H. WEISMAN August 2015 • Volume 41 • Number 3
Skin psoriasis is a major risk factor for the development of psoriatic arthritis. Recent studies have shown that delayed diagnosis is associated with long-term adverse outcomes. Screening questionnaires have revealed…
Epidemiologic studies have shown that, in patients with psoriatic arthritis (PsA), associated comorbidities may occur more frequently than expected. This article discusses related comorbidities in patients with PsA. Identifying these…
Traditional disease-modifying antirheumatic drugs (DMARD) remain the first-line treatment of psoriatic arthritis (PsA), despite lack of randomized controlled trials, and with evidence based on observational studies. Anti-tumor necrosis factor agents…
The introduction of highly effective therapies and clearly defined targets has altered the treatment paradigm in psoriatic arthritis (PsA). Validated classification criteria and outcome measures specific to PsA have helped…
Biologic medications, therapeutic proteins that inhibit or modulate proinflammatory immune cells and cytokines, have significantly altered clinicians’ ability to effectively treat psoriatic arthritis (PsA). The first widely used biologics have…
In the last decade, there have been significant advances in outcome measure research in psoriatic arthritis (PsA). In this article, the outcome measures for disease activity in individual key domains…
